These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 38506367)
1. Rapid FRET Assay for the Early Detection of Alpha-Synuclein Aggregation in Parkinson's Disease. Yu H; Feng R; Chen F; Wu Z; Li D; Qiu X ACS Chem Neurosci; 2024 Apr; 15(7):1378-1387. PubMed ID: 38506367 [TBL] [Abstract][Full Text] [Related]
2. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Ghanem SS; Majbour NK; Vaikath NN; Ardah MT; Erskine D; Jensen NM; Fayyad M; Sudhakaran IP; Vasili E; Melachroinou K; Abdi IY; Poggiolini I; Santos P; Dorn A; Carloni P; Vekrellis K; Attems J; McKeith I; Outeiro TF; Jensen PH; El-Agnaf OMA Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2109617119. PubMed ID: 35353605 [TBL] [Abstract][Full Text] [Related]
3. A FRET-based aptasensor for the detection of α-synuclein oligomers as biomarkers of Parkinson's disease. Saedi Z; Nikkhah M Anal Methods; 2022 Aug; 14(30):2937-2944. PubMed ID: 35861142 [TBL] [Abstract][Full Text] [Related]
4. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations. Sahay S; Ghosh D; Singh PK; Maji SK Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727 [TBL] [Abstract][Full Text] [Related]
5. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232 [TBL] [Abstract][Full Text] [Related]
6. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model. Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621 [TBL] [Abstract][Full Text] [Related]
7. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. Mehra S; Sahay S; Maji SK Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylated α-synuclein in diluted human serum as a biomarker for Parkinson's disease. Chen WR; Chen JC; Chang SY; Chao CT; Wu YR; Chen CM; Chou C Biomed J; 2022 Dec; 45(6):914-922. PubMed ID: 34974168 [TBL] [Abstract][Full Text] [Related]
9. Scutellarin inhibits the uninduced and metal-induced aggregation of α-Synuclein and disaggregates preformed fibrils: implications for Parkinson's disease. Zaidi FK; Deep S Biochem J; 2020 Feb; 477(3):645-670. PubMed ID: 31939603 [TBL] [Abstract][Full Text] [Related]
10. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species. Singh P; Bhat R ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654 [TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics. Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174 [TBL] [Abstract][Full Text] [Related]
12. Small molecule-based fluorescent probes for the detection of α-Synuclein aggregation states. Haque R; Maity D Bioorg Med Chem Lett; 2023 Apr; 86():129257. PubMed ID: 36966976 [TBL] [Abstract][Full Text] [Related]
13. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies. Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153 [TBL] [Abstract][Full Text] [Related]
14. Modulating α-synuclein propagation and decomposition: Implications in Parkinson's disease therapy. Li B; Xiao X; Bi M; Jiao Q; Chen X; Yan C; Du X; Jiang H Ageing Res Rev; 2024 Jul; 98():102319. PubMed ID: 38719160 [TBL] [Abstract][Full Text] [Related]
15. Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease. Zhang S; Liu YQ; Jia C; Lim YJ; Feng G; Xu E; Long H; Kimura Y; Tao Y; Zhao C; Wang C; Liu Z; Hu JJ; Ma MR; Liu Z; Jiang L; Li D; Wang R; Dawson VL; Dawson TM; Li YM; Mao X; Liu C Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34172566 [TBL] [Abstract][Full Text] [Related]
16. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897 [TBL] [Abstract][Full Text] [Related]
17. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease. Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273 [TBL] [Abstract][Full Text] [Related]
18. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis. Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838 [TBL] [Abstract][Full Text] [Related]
20. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models. Sato H; Kato T; Arawaka S Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]